Gilead Recalls Vistide Injection

Gilead Sciences announced a voluntary recall of Vistide (cidofovir injection) due to the presence of particulate matter found in some vials of a lot. Vistide is a nucleotide analogue indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS.

The affected lot number is B120217A with an expiration date of May 2015. This sterile, hypertonic solution is supplied in clear glass vials. Gilead has notified its distributors and customers by e-mail and recall letter and is arranging for return of all recalled product.

For more information call (800) 445-3235 or visit http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm340094.htm